OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple Myeloma

April 20th 2018

Nitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.

Dr. Wolf on the Treatment of High-Risk Patients With Multiple Myeloma

April 20th 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the treatment approach for patients with high-risk multiple myeloma.

Dr. Ginsburg Addresses Global Disparities in Cervical Cancer

April 19th 2018

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, addresses global disparities in cervical cancer.

Dr. Topalian on the Treatment of Nasopharyngeal Carcinoma

April 19th 2018

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery and Oncology, Johns Hopkins Medicine, discusses the treatment of patients with nasopharyngeal carcinoma.

Dr. Kaplan on Treating Solid Tumors in Pediatric Patients

April 19th 2018

Rosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with solid tumors.

Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLC

April 19th 2018

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutation

Dr. Paik on Resistance Mutations in NSCLC

April 18th 2018

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses resistance mutations in patients with non–small cell lung cancer (NSCLC).

Dr. Janicek on Genetic Testing in Patients With Ovarian Cancer

April 18th 2018

Mike Janicek, MD, medical director, Division of Genetics, Arizona Oncology, discusses the use of genetic testing in patients with ovarian cancer.

Dr. Chase on the Presentation of Uterine Sarcomas

April 18th 2018

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the presentation of uterine sarcomas.

Dr. Kris on Combination Chemotherapy Approaches in NSCLC

April 18th 2018

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Hellmann on Tumor Mutational Burden in NSCLC

April 18th 2018

Matthew D. Hellmann, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role tumor mutational burden (TMB) plays in determining combination therapies for patients with non–small cell lung cancer (NSCLC).

Dr. Drilon on Targeted Therapies for Patients With ROS1-Rearranged Lung Cancer

April 18th 2018

Alexander Drilon, MD, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses targeted agents for patients with ROS1-rearranged lung cancer.

Dr. Rudin on Significance of the KEYNOTE-021 in Patients With NSCLC

April 17th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of KEYNOTE-021.

Dr. Palmer on Molecular Abnormalities in Myeloproliferative Diseases

April 16th 2018

Jeanne M. Palmer, MD, hematologist oncologist, Mayo Clinic, discusses molecular abnormalities in myeloproliferative diseases, including polycythemia vera (PV) and the use of next-generation sequencing in identifying these mutations.

Dr. Willmott on Mechanisms of Resistance in Ovarian Cancer

April 16th 2018

Lyndsay J. Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses the mechanisms of resistance to PARP inhibitors that have been identified in ovarian cancer.

Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

April 16th 2018

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

Dr. Mesa Discusses the Management of Patients With MPNs

April 14th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the management of patients with myeloproliferative neoplasms.

Dr. Yu on the Importance of a Genetic Counselor in Prostate Cancer

April 14th 2018

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses the importance of a genetic counselor in the treatment of patients with prostate cancer.

Dr. Andtbacka Discusses Next Steps With T-VEC in Melanoma

April 14th 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the future of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.

Dr. Stewart on the Role of Transplant in Multiple Myeloma

April 13th 2018

Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.